John heads up toXcel's primary European-based operations from our soon-to-be-opened new office in the
Cambridge, UK area. He holds academic qualifications from UK universities (MIBiol, MPhil and PhD). John is
broadly based in pharmacology and toxicology, with emphasis on the management of R&D programs for
chemicals and pharmaceuticals, and with specialized focus on in vivo and in vitro drug metabolism,
pharmaco/toxicokinetics, mechanistic toxicology, and bioanalysis including renal and nasal toxicology. John's
multidisciplinary training also includes the use of in vitro systems to aid in the selection and development of
lead candidates, and leadership in a variety of novel research programs.

Prior to joining toXcel, John lived in North America and worked as the Director of Drug Metabolism and
Pharmacokinetics for a major international CRO based in Montreal. During this time, he gained considerable
experience in working on new NCE's for companies ranging in size from large multinational pharmaceutical to
small biotech companies. During his career, John also has worked in senior scientific and directorship
positions for major international, UK-based chemical and agrochemical companies. In addition, he has
extensive hands-on experience and familiarity with business start-up activities including due diligence,
laboratory facilities acquisition, design and set-up, and equipment procurement.

In his new role at toXcel, John will provide leadership in further expanding our existing client services in the
pharmaceutical R&D sector, as well as our EU regulatory representation and dossier support for industrial
chemicals, antimicrobials, agrochemicals and inerts under the EU REACH program and the Biocidal Products
Directive (98/8/EC), Cosmetics Directive (76/768/EEC), Plant Protection Products Directive (91/414/EEC),
and Medicinal Products Directive (2001/83/EC)